Cardiolite MPI in Pediatric Kawasaki Disease

Phase 3, open-label trial of Tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate in Kawasaki disease (KD) (2 arms), sponsored by Lantheus Holdings, Inc. Primary endpoint: Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac Events at 3 years. Started Aug 2005; status: completed.